Under the December 1 and 1998 are assessed to the second

Application Number		10623009	
Filing Date		2003-07-18	
First Named Inventor	Micha	ael Novak	
Art Unit		2161	
Examiner Name	K. Pa	dmanabhan	
Attorney Docket Number		MS#303011.01 (5057)	

				U.S.	PATENTS	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the Add button.	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030084460	A1	2003-05-01	Chung et al.	
	2	20050203992	A1	2005-09-15	Tanaka et al.	
If you wisi	h to a	dd additional U.S. Publ	ished Ap	plication citatio	n information please click the Ad	d button.

If you wish to add additional	U.S. Published	Application citation	information plea	ase click the	Add button

	FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	75
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

#### 

Examiner Initials*	Cite No	include name of the aumor (in CAPTAL LETTERS), the of the article (when appropriate), the of the tem (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	ŢS
	1		
	_		_

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at sum-USPTO.COU/or MREP 901.04. If Steer office that insued the document, by the how-letter code (WPO Standard ST3.) Ser department patent document, by many continuents, by an obstance of the present patent and present insurance of the seal number of the patent document.

\*\*India of document by the popropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if English impragate princations is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10623009	
	Filing Date		2003-07-18	
First Named Inventor Micha		Micha	nel Novak	
	Art Unit		2161	
Examiner Name K. Pa		K. Pa	dmanabhan	
Attorney Docket Number		er	MS#303011.01 (5057)	

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the	appropriate	selection(s):
---------------	----------	-------------	----------	-------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.39(c).

- See attached certification statement
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Frank R. Acovino

None

Name/Print

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Frank R. Agovino/	Date (YYYY-MM-DD)	2006-10-20

Registration Number

27416

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to lie (and by the USPTO to process) an application. Contidentality is governed by \$5 U.S. C. 12 and 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this from and/or suggestions for reducing his burden, should be sent to the Chief Information Officer, U.S. Petert and Trademark Office, V.S. operatment of Commence, P.O. Box 1450, Alexandric, V.S. 2371-1450. DIOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrica, V.S. 2371-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given centain information in connection with your submission of the article from related to a partent application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); 2) familishing of the information solicided is outlinatly, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademax (Chris e is to process and/or examine your submission related to a patient agriculture or patient. If you do not farmed the requested process and/or examine your submission related to a patient agriculture or patient. If you do not farmed the requested requirement of the patient of the patient and the patient of the patien

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be discbeed, as a routine use, to the Administrator, General Services, or hisher designed, during an inspection of records conducted by GAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2508. Such disclosure shall be made in accordance with the GAS regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relaterminations be abust individuals.
- A record from this system of records may be disolosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 152(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the arcord was filed in an application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public in specification and is used patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.